Douglas Lytle Mayers MD
Exec VP and CMO Idenix Pharmaceuticals Cambridge, MA
Join to View Full Profile
41 Dexter StreetMalden, MA 02148
Phone+1 617-335-4708
Dr. Mayers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Virginia Medical CenterResidency, Internal Medicine, 1978 - 1980
Perelman School of Medicine at the University of PennsylvaniaClass of 1978
Certifications & Licensure
VA State Medical License 1981 - 2026
MI State Medical License 1998 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
Publications & Presentations
PubMed
- 13 citationsATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens.Katherine E. Squires, Douglas L. Mayers, Gregory R. Bluemling, Alexander A. Kolykhalov, David B. Guthrie
Antimicrobial Agents and Chemotherapy. 2020-08-20 - 17 citationsA randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4Bradley D. Vince, J. Hill, Eric Lawitz, William O'Riordan, Lynn R. Webster
Journal of Hepatology. 2014-05-01 - 8 citationsIDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.Jacob Lalezari, Terry Box, William O'Riordan, Purvi Mehra, Tuan V. Nguyen
Antiviral Therapy. 2013-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
